240 related articles for article (PubMed ID: 8354307)
1. Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs.
Sader HS; Jones RN
Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):384-91. PubMed ID: 8354307
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.
Goldstein EJ; Citron DM; Tyrrell KL; Merriam CV
Antimicrob Agents Chemother; 2013 Jun; 57(6):2620-30. PubMed ID: 23529731
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwide.
Hoban DJ; Jones RN; Yamane N; Frei R; Trilla A; Pignatari AC
Diagn Microbiol Infect Dis; 1993; 17(4):299-305. PubMed ID: 8112045
[TBL] [Abstract][Full Text] [Related]
4. In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms.
Chen HY; Livermore DM
J Antimicrob Chemother; 1994 May; 33(5):949-58. PubMed ID: 8089068
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vitro activity of biapenem, a new carbapenem antibiotic.
Clarke AM; Zemcov SJ
Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):377-84. PubMed ID: 8354306
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro antibacterial activity of the new carbapenem meropenem (SM-7338).
Visser MR; Hoepelman IM; Beumer H; Rozenberg-Arska M; Verhoef J
Eur J Clin Microbiol Infect Dis; 1989 Dec; 8(12):1061-4. PubMed ID: 2695328
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa.
Shibata K; Adachi Y; Kato E; Nagano R; Fuse A; Hashizume T; Ohtake N; Okamoto O; Nakagawa S
J Antibiot (Tokyo); 1997 Feb; 50(2):135-8. PubMed ID: 9099222
[TBL] [Abstract][Full Text] [Related]
9. Antibacterial in vitro-activity of meropenem against 200 clinical isolates in comparison to 11 selected antibiotics.
Lang C; Beuth J; Ko HL; Tunggal L; Pulverer G
Zentralbl Bakteriol; 1992 Dec; 277(4):485-92. PubMed ID: 1303691
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes.
Aldridge KE; Morice N; Schiro DD
Antimicrob Agents Chemother; 1994 Apr; 38(4):889-93. PubMed ID: 8031067
[TBL] [Abstract][Full Text] [Related]
11. Antibacterial properties of meropenem towards clinical isolates, beta-lactamase producers and laboratory mutants.
Wiedemann B; Zühlsdorf M
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():197-205. PubMed ID: 2681124
[TBL] [Abstract][Full Text] [Related]
12. Comparative in-vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum beta-lactamases.
Chanal C; Sirot D; Chanal M; Cluzel M; Sirot J; Cluzel R
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():133-41. PubMed ID: 2808205
[TBL] [Abstract][Full Text] [Related]
13. Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by beta-lactamases.
Yang Y; Bhachech N; Bush K
J Antimicrob Chemother; 1995 Jan; 35(1):75-84. PubMed ID: 7768785
[TBL] [Abstract][Full Text] [Related]
14. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide.
Pfaller MA; Jones RN
Diagn Microbiol Infect Dis; 1997 Aug; 28(4):157-63. PubMed ID: 9327242
[TBL] [Abstract][Full Text] [Related]
15. Multicenter in vitro evaluation of SM-7338, a new carbapenem.
Jones RN; Aldridge KE; Allen SD; Barry AL; Fuchs PC; Gerlach EH; Pfaller MA
Antimicrob Agents Chemother; 1989 Apr; 33(4):562-5. PubMed ID: 2658796
[TBL] [Abstract][Full Text] [Related]
16. In-vitro activity of meropenem against clinical isolates obtained in Canada.
Clarke AM; Zemcov SJ
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():47-55. PubMed ID: 2808216
[TBL] [Abstract][Full Text] [Related]
17. In-vitro activity of meropenem against clinical isolates in a multicentre study in Italy.
Schito GC; Sanna A; Chezzi C; Ravizzola G; Leone F; Molinari G; Menozzi MG; Pirali F
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():57-72. PubMed ID: 2681128
[TBL] [Abstract][Full Text] [Related]
18. In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I.
Edwards JR; Turner PJ; Wannop C; Withnell ES; Grindey AJ; Nairn K
Antimicrob Agents Chemother; 1989 Feb; 33(2):215-22. PubMed ID: 2655530
[TBL] [Abstract][Full Text] [Related]
19. Activity of meropenem against imipenem-resistant bacteria and selection in vitro of carbapenem-resistant Enterobacteriaceae.
Piddock LJ; Turner HL
Eur J Clin Microbiol Infect Dis; 1992 Dec; 11(12):1186-91. PubMed ID: 1291320
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers.
Pitkin DH; Sheikh W; Nadler HL
Clin Infect Dis; 1997 Feb; 24 Suppl 2():S238-48. PubMed ID: 9126699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
